The Shadow Formulary: How Pharmacy Benefit Managers Ration Medications Beyond the Reach of Public Accountability

When the United States Food and Drug Administration approves a drug, the implicit public understanding is that patients who need that medication may obtain it. The approval process is rigorous, publicly documented, and subject to scientific and legal scrutiny. What happens afterward, however, occupies a far less transparent domain — one in which private intermediaries exercise extraordinary gatekeeping authority over which approved medications patients can realistically access and at what cost. Pharmacy benefit managers, or PBMs, and the formulary systems they administer have become, in functional terms, a parallel regulatory apparatus. Unlike the FDA, they operate without public hearings, without published evidentiary standards, and without meaningful mechanisms for democratic challenge.

What a Formulary Does — and What It Conceals

A pharmacy formulary is, at its most basic, a tiered list of covered medications maintained by an insurer or its contracted PBM. Drugs placed on lower tiers carry lower cost-sharing obligations for the patient; those relegated to higher tiers may require substantial co-pays or co-insurance that can render a medication financially inaccessible even when it is technically covered. Drugs excluded from a formulary entirely require patients to navigate prior authorization processes, appeal denials, or pay full out-of-pocket costs — outcomes that, in practice, often mean patients go without.

The clinical logic governing these placement decisions is rarely disclosed. The three dominant PBMs — CVS Caremark, Express Scripts, and OptumRx — collectively manage pharmacy benefits for the majority of insured Americans, yet their formulary construction methodologies are treated as proprietary business information. Rebate negotiations with pharmaceutical manufacturers, which substantially influence tier placement, occur in contractual secrecy. The result is a system in which the financial interests of intermediaries may bear as much or more weight on a patient's medication access as the clinical evidence base reviewed during FDA approval.

Tiering as a Mechanism of Stratified Access

The distributional consequences of formulary architecture are not incidental. Research has consistently demonstrated that high cost-sharing requirements reduce medication adherence across patient populations, with the steepest effects concentrated among lower-income individuals and those managing chronic conditions that require ongoing pharmacotherapy. When a formulary places a first-line antidiabetic agent on a specialty tier with a monthly co-pay exceeding two hundred dollars, the practical effect is rationing — not by clinical criteria, but by economic capacity.

This dynamic is compounded by the practice of formulary exclusions, through which PBMs remove entire drug classes or specific branded medications from coverage lists, often in exchange for manufacturer rebates that benefit the PBM and employer sponsors rather than the patient at the pharmacy counter. The Affordable Care Act established minimum coverage requirements and prohibited certain discriminatory benefit designs, but it did not regulate formulary construction directly. Patients who discover mid-treatment that their medication has been removed from their plan's formulary during an annual review period face disruptions that carry genuine clinical risk, particularly in psychiatric, oncological, and immunological care contexts.

A Governance Gap Without Parallel

The governance architecture surrounding PBMs is notably fragmented. Federal oversight is limited: the Employee Retirement Income Security Act preempts most state-level PBM regulations for employer-sponsored plans, creating a regulatory vacuum that states cannot fill and that Congress has been slow to address. Legislative proposals to require greater PBM transparency, mandate pass-through pricing models, or establish fiduciary duties to plan beneficiaries have advanced through committee stages with limited success over multiple congressional sessions.

What distinguishes this governance gap from other areas of pharmaceutical policy is its deliberate obscurity. The FDA operates under statutory mandates to publish its evidentiary reasoning. Medicare's coverage determinations through the Centers for Medicare and Medicaid Services are subject to notice-and-comment procedures. PBM formulary decisions carry none of these procedural requirements. A patient denied access to a prescribed medication has no reliable mechanism to understand why that decision was made, who made it, or what evidence — clinical or financial — informed it.

European Frameworks as a Reference Point

Comparative analysis of European formulary governance reveals that transparent, clinically grounded coverage decision-making is administratively achievable. The United Kingdom's National Institute for Health and Care Excellence publishes detailed technology appraisal guidance that explicates the clinical and cost-effectiveness evidence underlying each coverage recommendation. Germany's Institute for Quality and Efficiency in Health Care conducts public benefit assessments for newly approved drugs, with findings that directly inform pricing negotiations. France's Haute Autorité de Santé similarly assigns medical service improvement ratings that are publicly documented and clinically justified.

None of these systems is without limitation. Critics note that health technology assessment bodies can be slow to approve innovative therapies and may apply cost-effectiveness thresholds that disadvantage rare disease treatments. Nevertheless, each framework provides patients, clinicians, and policymakers with a documented rationale for coverage decisions — a basic standard of accountability that the American PBM system does not approach.

The relevance for US reform is not that European single-payer or social insurance models should be transplanted wholesale — a proposition that faces well-documented political and structural barriers — but rather that transparency and clinical justification requirements can be imposed on formulary decision-making regardless of the underlying insurance architecture. A multi-payer system is not inherently incompatible with public accountability standards for coverage determinations.

The Policy Imperative

Several reform pathways merit serious legislative consideration. First, mandatory disclosure of formulary construction methodologies and the role of rebate negotiations in tier placement decisions would enable independent scrutiny of whether financial incentives are distorting clinical coverage logic. Second, standardized prior authorization timelines and independent external review rights for formulary exclusion decisions would provide patients with procedural protections currently absent from most commercial plan designs. Third, extending fiduciary obligations to PBMs — requiring that they act in the interests of plan beneficiaries rather than plan sponsors or manufacturer rebate partners — would restructure the incentive environment within which formulary decisions are made.

The central issue is not whether formularies serve a legitimate function. Managed lists of covered medications can, in principle, promote evidence-based prescribing and cost discipline within a healthcare system. The issue is whether a system of this consequence — one that effectively determines whether a patient can afford the treatment their physician has prescribed — should operate in structural opacity, insulated from the accountability norms applied to every other major actor in the American pharmaceutical regulatory landscape.

The FDA's approval of a medication does not guarantee its accessibility. That gap, between regulatory approval and practical patient access, is currently filled by private intermediaries whose decision-making logic remains largely invisible. Closing that accountability deficit is not a peripheral policy concern. It is a foundational question about who, in the American health system, actually holds the authority to decide which patients receive care.